Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsPRNewsWire • 05/08/23
Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?Zacks Investment Research • 05/04/23
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist TrialsPRNewsWire • 04/26/23
NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical CandidatesBusiness Wire • 01/04/23
Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of ChondrosarcomaPRNewsWire • 11/16/22
Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsPRNewsWire • 11/07/22
Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 StudyPRNewsWire • 10/04/22
Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin DeficiencyPRNewsWire • 10/03/22
European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of ChondrosarcomaPRNewsWire • 08/15/22
Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate HighlightsPRNewsWire • 08/08/22
Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford FinancePRNewsWire • 06/30/22
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly DosingPRNewsWire • 05/16/22